SCHEMBL4887059

SCHEMBL4887059

COc1cc(CCC(=O)O)cc(Br)c1OCc1cccc(Br)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 11/20 0.80
THRA P10827 10/20 0.80
ESR1 P03372 1/20 0.80
NR3C1 P04150 1/20 0.80
PGR P06401 1/20 0.80
NR3C2 P08235 1/20 0.80
AR P10275 1/20 0.80
FFAR1 O14842 2/20 0.60
FFAR4 Q5NUL3 1/20 0.60
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HSD17B10 Q99714 2/20 0.50
MAPT P10636 2/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
BLM P54132 1/20 0.50
PARP15 Q460N3 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898980 0.89 THRA (1.00) THRBTHRAESR1NR3C1PGR
SCHEMBL4896330 0.82 THRA (0.74) THRBTHRAESR1NR3C1PGR
SCHEMBL29085941 0.81 THRA (0.66) THRBTHRAESR1NR3C1PGR
SCHEMBL4891205 0.80 THRA (1.00) THRBTHRAESR1NR3C1PGR
SCHEMBL4272376 0.80 THRA (0.77) THRBTHRAESR1NR3C1PGR
SCHEMBL5072110 0.79 THRA (0.81) THRBTHRAESR1NR3C1PGR
SCHEMBL5668021 0.79 MAOB (0.57) THRBTHRAESR1NR3C1PGR
SCHEMBL4896873 0.78 THRA (1.00) THRBTHRAESR1NR3C1PGR
SCHEMBL4897770 0.78 APP (0.61) THRBTHRAESR1NR3C1PGR
SCHEMBL4897767 0.78 APP (0.61) THRBTHRAESR1NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7005538-B1 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders KARO BIO AB (SE) 2006-02-28 US claimed
WO-2001036365-A2 THYROID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIAC AND METABOLIC DISORDERS KARO BIO AB (SE) 2001-05-25 WO claimed
US-20080027096-A1 Novel Pharmaceutical Compositions KARO BIO AB (SE) 2008-01-31 US disclosed
US-7319163-B2 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders KARO BIO AB (SE) 2008-01-15 US disclosed
EP-1729756-A2 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2006-12-13 EP disclosed
US-7005538-B1 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders KARO BIO AB (SE) 2006-02-28 US disclosed
US-20050267206-A1 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders MALM JOHAN 2005-12-01 US disclosed
WO-2005094810-A2 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2005-10-13 WO disclosed
WO-2001036365-A2 THYROID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIAC AND METABOLIC DISORDERS KARO BIO AB (SE) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267206-A1 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders TSHR, THRB, THRA THRB 2/4885THRA 3/4885ESR1 1026/4885
US-20080027096-A1 Novel Pharmaceutical Compositions AR, NR5A1, CYP17A1 THRB 792/4885THRA 559/4885ESR1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.